STOCK TITAN

Mereo Biopharma Group Plc - MREO STOCK NEWS

Welcome to our dedicated news page for Mereo Biopharma Group Plc (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo Biopharma Group Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mereo Biopharma Group Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mereo Biopharma Group Plc's position in the market.

Rhea-AI Summary
Mereo BioPharma Group plc (MREO) announced CEO Dr. Denise Scots-Knight will participate in a Fireside Chat at the Needham Virtual Healthcare Conference. The presentation will be on April 9, 2024, at 10:15am ET / 03:15pm BST, with a live webcast accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
-
Rhea-AI Summary
Mereo BioPharma Group plc announced financial results for 2023, highlighting progress in Phase 2/3 Orbit and Phase 3 Cosmic studies of setrusumab in Osteogenesis Imperfecta. Partnering discussions for alvelestat are advancing, with cash of $57.4 million as of December 31, 2023, expected to fund operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
-
Rhea-AI Summary
Mereo BioPharma Group plc (NASDAQ: MREO) announced that Dr. Denise Scots-Knight, CEO, will participate in a Fireside Chat at Leerink Partners Global Biopharma Conference. The live webcast can be accessed on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
conferences
Rhea-AI Summary
Mereo BioPharma Group plc (MREO) expects to complete enrollment in the Phase 3 portion of the Orbit Study and Phase 3 Cosmic Study for Osteogenesis Imperfecta treatment by partner Ultragenyx by 1Q 2024 and 1H 2024, respectively. The company also signed a global licensing deal for leflutrozole and reiterated its cash runway guidance into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
none
-
Rhea-AI Summary
Mereo BioPharma Group plc provides an update on recent program developments and third quarter 2023 financial information. Setrusumab achieves a 67% reduction in annualized fracture rate in patients with osteogenesis imperfecta. Alvelestat shows significant effects on lung disease. Etigilimab shows promising efficacy in solid tumors. The Company has cash and short-term deposits of £51.2 million ($62.4 million) as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
Rhea-AI Summary
Mereo BioPharma CEO to participate in Fireside Chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
conferences
Rhea-AI Summary
Mereo BioPharma announces unaudited interim financial results for H1 2023 and provides update on recent corporate highlights
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
conferences
-
Rhea-AI Summary
Mereo BioPharma presents data from Phase 2 trial of alvelestat for Alpha-1 Antitrypsin Deficiency-associated Lung Disease at ATS2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
Rhea-AI Summary
Mereo BioPharma Group plc (NASDAQ: MREO) has regained compliance with the minimum bid price requirement under the Nasdaq Listing Rules. The company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, achieving compliance on May 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
none
Mereo Biopharma Group Plc

Nasdaq:MREO

MREO Rankings

MREO Stock Data

381.50M
244.74M
0.54%
65.97%
1.66%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
1 Cavendish Place

About MREO

mereo is a new uk-based speciality biopharmaceutical company focussed on the acquisition and rapid development of innovative medicines that have the potential to transform patient quality of life and improve human health. mereo intends to optimise the commercial value of programmes by entering into partnering deals at key value inflection points or, for selected opportunities, commercialising products itself. mereo is building a strong pipeline of innovative medicines, particularly focused in rare and specialist disease areas, through the acquisition of validated, mid-stage development programmes from large biopharmaceutical companies. mereo has access to an extensive network of experts with experience across multiple clinical disciplines for the clinical development of its portfolio.